James Manuso - Oct 18, 2024 Form 4 Insider Report for Kintara Therapeutics, Inc. (KTRA)

Role: Director
Signature: /s/ Dan Dearborn as Power of Attorney for James Manuso
Stock symbol: KTRA
Transactions as of: Oct 18, 2024
Transactions value $: $0
Form type: 4
Date filed: 10/22/2024, 08:36 PM
Previous filing: Jun 13, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KTRA	Options (Right to Buy)	Award	$0	+13.6K		$0.00	13.6K	Oct 18, 2024	Common Stock	13.6K	$3.69	Direct	F1
transaction	KTRA	Options (Right to Buy)	Award	$0	+13.6K		$0.00	13.6K	Oct 18, 2024	Common Stock	13.6K	$4.14	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."

Content

Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."